David Vs Goliath – Flarin’s Macmillen On Slugging It Out With The Heavyweights

21 May 2020

HBW Insight Exclusive: Flarin boss Andrew Macmillen on competing with the big OTC incumbents as a lean, innovation-focused company.

Box fighters trainning outdoor . Mixed media — • Source: Shutterstock

With its unique lipid technology, UK ibuprofen brand Flarin has been increasing market share up against heavy hitting brands like GlaxoSmithKline’s Voltarol and Reckitt Benckiser’s Nurofen since launching at the beginning of 2018.

Relying on lipids – a macrobiomolecule derived from pharmaceutical-grade fats of plant origin – rather than water-based liquids for delivery, Flarin’s 200mg of ibuprofen is not absorbed in the stomach but in the small

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Danes Get OTC Access To ED Treatment

08 May 2025

• By Tom Gallen

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

07 May 2025

• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

People On The Move: Appointments At Haleon, Wellnex, Orkla

06 May 2025

• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.